Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Hawkey

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
BMJ Open|July 12, 2014
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemiaThomas M MacDonald, Ian Ford, George Nuki, et al.
Lancet (London, England)|November 12, 2020
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trialIsla S Mackenzie, Ian Ford, George Nuki, et al.
Trials|April 22, 2022
Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney diseaseHugh Gallagher, Jennifer Dumbleton, Tom Maishman, et al.
Lancet (London, England)|August 25, 2004
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trialMichael E Farkouh, Howard Kirshner, Robert A Harrington, et al.
Health Technology Assessment (Winchester, England)|March 29, 2024
Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluationIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
Lancet (London, England)|October 10, 2022
Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trialIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
JAMA|December 17, 2015
Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical TrialChristopher J Hawkey, Matthieu Allez, Miranda M Clark, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
BMJ Open|July 12, 2014
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemiaThomas M MacDonald, Ian Ford, George Nuki, et al.
Lancet (London, England)|November 12, 2020
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trialIsla S Mackenzie, Ian Ford, George Nuki, et al.
Trials|April 22, 2022
Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney diseaseHugh Gallagher, Jennifer Dumbleton, Tom Maishman, et al.
Lancet (London, England)|August 25, 2004
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trialMichael E Farkouh, Howard Kirshner, Robert A Harrington, et al.
Health Technology Assessment (Winchester, England)|March 29, 2024
Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluationIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
Lancet (London, England)|October 10, 2022
Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trialIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
JAMA|December 17, 2015
Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical TrialChristopher J Hawkey, Matthieu Allez, Miranda M Clark, et al.
Pageof 5